EQUIZONE 50/100- phenylbutazone powder
A&G Pharmaceuticals

EQUIZONE 50/100 (phenylbutazone) Powder

(phenylbutazone)

Powder

For Oral Use In Horses Only

NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Federal law prohibits the extralabel use of this product in female dairy cattle 20 months of age or older.

DESCRIPTION

Phenylbutazone chemically is 4-butyl-1,2-diphenyl-3,5-pyrazolidinedione.

$C_{19}H_{20}N_2O_2$

Mol. Wt. 308.38

Each 10 grams of powder contains 1 gram phenylbutazone

INDICATIONS

Phenylbutazone is for the relief of inflammatory conditions associated with the musculoskeletal system in horses. In the treatment of inflammatory conditions associated with infections, specific anti-infective therapy should be used concurrently.

DOSAGE AND ADMINISTRATION

For Horses Only: Administer orally (using the 0.6 ounce (18 mL) scoop provided) on a small amount of palatable feed and mix well. Give 1 to 2 level scoops per 500 pounds of body weight, but do not exceed 4 scoops per animal daily. Use the high dose for the first 48 hours, then gradually reduce to a maintenance dose.

CONTRAINDICATIONS

Use with caution in patients who have a history of drug allergy.

WARNING

Do not use in horses intended for human consumption.

HUMAN WARNING

Keep this and all medications out of the reach of children. Dispense in tight, child resistant containers.

PRECAUTION

Concomitant use with other anti-inflammatory drugs, such as NSAIDs or corticosteroids, should be avoided or closely monitored.

CLINICAL PHARMACOLOGY

Phenylbutazone was first synthesized in 1948 and introduced into human medicine in 1949. Kuzell (1), (2), (3), Payne (4), Fleming (5) and Denko (6) demonstrated the clinical effectiveness of phenylbutazone in gout, gouty arthritis, acute arthritis, acute rheumatism and various other rheumatoid disorders in humans. Fabre (7), Domenjoz (8), Wilhelmi (9) and Yourish (10) have established the anti-rheumatic and anti-inflammatory activity of phenylbutazone. It is entirely unrelated to the steroid hormones. Toxicity of phenylbutazone has been investigated in rats and mice (11) and dogs (12). Phenylbutazone has been used by Camberos (13) in thoroughbred horses. Favorable results were reported in cases of traumatism, muscle rupture, strains and inflammations of the third phalanx. Results were not as favorable in the period treatment of osteoarthritis of the stifle and hip, arthrosis of the trapezious muscles and general arthritis. Sutter (14) reported a favorable response in chronic equine arthritis of long duration, fair results in severely bruised mare and poor results in two cases where the condition was limited to the third phalanx.

HOW SUPPLIED

Phenylbutazone Powder is supplied in 1.1 lb (0.5 kg) jars and 2.2 lb (1 kg) jars each containing a dispensing scoop. One level scoop delivers 10 grams of powder containing 1 gram of phenylbutazone.

References

1. Kuzell, WC, Schaffarzick, RW, Naughler, WE, Gandia, C, and Mankle, EA: A.M.A. Arch. Inst. Med., 92:646 (1953).
2. Kuzell, WC, Schaffarzick, RW, Brown, B, and Mankle, EA: J.A.M.A., 149:729 (1952).
3. Kuzell, WC, and Schaffarzick, RW: Calif. Med., 77:319 (1952).
4. Payne, RW, Shelter, MR, Farr, CH, Hellbaum, AA, and Ishmall, WK: J. Lab. Clin. Med., 45:331 (1955).
5. Fleming, J, and Will, G: Ann. Rheumat., Dis., 12:95 (1953).
6. Denko, CW, and Rumi, D: American Pract., 6:1865 (1955).
7. Fabre, J, et al: Semain. Hop. (Paris), 31:87 (1955).
8. Domenjoz, R, et al: Arzneimittel-Forsch, 5:488 (1955).
9. Wilhelmi, G, and Pulver, R: Arzneimittel-Forsch, 5:221 (1955).
10. Yourish, W, Paton, B, Brodie, B, and Burns, J: A.M.A. Arch. Ophth., 53:264 (1955).
11. Hazelton, LW, Tusing, TW, and Hollana, EG: J. Pharmacol. Exper. Ther., 109:387

(1953).
12. Ogilvie, FB, and Sutter, MD: Vet. Med. 52:492 (1957).
13. Camberos, HR: Rev. Med. Vet. (Buenos Aries), 38:9 (1956).
14. Sutter, MD: Vet. Med., 53:83 (1958).

Principal Display Panel - EQUIZONE 50™ 50 (1.1 lb jar)

NDC 57699-001-11

EQUIZONE50™

(phenylbutazone)

Powder

For Oral Use In Horses Only

NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extralabel use of this product in female dairy cattle 20 months of age or older.

Net Contents: 1.1 lb (0.5 kg)

Approved by FDA under ANADA # 200-334



chronic equine arthritis of long duration, fair results in severely bruised mare and poor results in two cases where the condition was limited to the third phalanx.

HOW SUPPLIED: EQUIZONE 50 Powder is supplied in 1.1 lb (0.5 kg) jars each containing a dispensing scoop. One level scoop delivers 10 grams of powder containing 1 gram of phenylbutazone.

Store at room temperature, 15°-30°C (59°-86°F).

References:

1. Kuzell, WC, Schaffarzick, RW, Naughler, WE, Gandia, C, and Mankle, EA: A.M.A. Arch. Inst. Med., 92:646 (1953).
2. Kuzell, WC, Schaffarzick, RW, Brown, B, and Mankle, EA: J.A.M.A., 149:729 (1952).
3. Kuzell, WC, and Schaffazick, RW: Calif. Med., 77:319 (1952).
4. Payne, RW, Shelter, MR, Farr, CH, Hellbaum, AA, and Ishmall, WK: J. Lab. Clin. Med., 45:331 (1955).
5. Fleming, J, and Will, G: Ann. Rheumat., Dis., 12:95 (1953).

6. Denko, CW, and Rumi, D: American Pract., 6:1865 (1955).
7. Fabre, J, et al: Semain. Hop. (Paris), 31:87 (1955).
8. Domenjoz, R, et al: Arzneimittel-Forsch, 5:488 (1955).
9. Wilhelmi G, and Pulver, R: Arzneimittel-Forsch, 5:221 (1955).
10. Yourish, W, Paton, B, Brodie, B, and Burns, J: A.M.A. Arch. Ophth., 53:264 (1955).
11. Hazelton, LW, Tusing, TW, and Hollana, EG: J. Pharmacol. Exper. Ther., 109:387 (1953).
12. Ogilvie, FB, and Sutter, MD: Vet. Med. 52:492 (1957).
13. Camberos, HR: Rev. Med. Vet. (Buenos Aires), 38:9 (1956).
14. Sutter, MD: Vet. Med., 53:83 (1958).

Approved by FDA under ANADA # 200-334

Rev. 10-22

Each 10 grams of powder contains:
Phenylbutazone ..... 1 gram
One level scoop delivers 10 grams of powder.

WARNING: Do not use in horses intended for human consumption.

HUMAN WARNINGS: Keep this and all medications out of the reach of children. Dispense in tight, child resistant containers.

PRECAUTION: Concomitant use with other anti-inflammatory drugs, such as NSAIDs or corticosteroids, should be avoided or closely monitored.

Store at room temperature, 15°-30°C (59°-86°F).

EQUIZONE 50™ is a trademark of A & G Pharmaceuticals, Inc.

Manufactured for
A & G Pharmaceuticals, Inc.
Jackson, NJ 08527

EQUIZONE 50™
(phenylbutazone)

Powder
For Oral Use In Horses Only

NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extralabel use of this product in female dairy cattle 20 months of age or older.

DESCRIPTION: Phenylbutazone chemically is 4-butyl-1,2-diphenyl-3,5-pyrazolidinedione.

$C_{19}H_{20}N_2O_2$

Mol. Wt. 308.38

Each 10 grams of powder contains 1 gram phenylbutazone

INDICATIONS: Phenylbutazone is for the relief of inflammatory conditions associated with the musculoskeletal system in horses. In the treatment of inflammatory conditions associated with infections, specific anti-infective therapy should be used concurrently.

DOSAGE AND ADMINISTRATION: For Horses Only: Administer orally (using the 0.6 ounce (18 mL) scoop provided) on a small amount of palatable feed and mix well. Give 1 to 2 level scoops per 500 pounds of body weight, but do not exceed 4 scoops per animal daily. Use the high dose for the first 48 hours, then gradually reduce to a maintenance dose.

CONTRAINDICATIONS: Use with caution in patients who have history of drug allergy.

WARNING: Do not use in horses intended for human consumption.

HUMAN WARNINGS: Keep this and all medications out of the reach of children. Dispense in tight, child resistant containers.

PRECAUTION: Concomitant use with other anti-inflammatory drugs, such as NSAIDs or corticosteroids, should be avoided or closely monitored.

CLINICAL PHARMACOLOGY:
Phenylbutazone was first synthesized in 1948 and introduced into human medicine in 1949. Kuzell (1), (2), (3), Payne (4), Fleming (5) and Denko (6) demonstrated the clinical effectiveness of phenylbutazone in gout, gouty arthritis, acute arthritis, acute rheumatism and various other rheumatoid disorders in humans. Fabre (7), Domenjoz (8), Wilhelmi (9) and Yourish (10) have established the anti-rheumatic and anti-inflammatory activity of phenylbutazone. It is entirely unrelated to the steroid hormones.

Toxicity of phenylbutazone has been investigated in rats and mice (11) and dogs (12).

Phenylbutazone has been used by Camberos (13) in thoroughbred horses. Favorable results were reported in cases of traumatism, muscle rupture, strains and inflammations of the third phalanx. Results were not as favorable in the period treatment of osteoarthritis of the stifle and hip, arthrosis of the trapezious muscles and general arthritis. Sutter (14) reported a favorable response in

Principal Display Panel - EQUIZONE 100™ (2.2 lb jar)

NDC 57699-001-22

EQUIZONE 100™

(phenylbutazone)

Powder

For Oral Use In Horses Only

NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extralabel use of this product in female dairy cattle 20 months of age or older.

Net Contents: 2.2 lb (1 kg)

Approved by FDA under ANADA # 200-334

INDICATIONS: Phenylbutazone is for the relief of inflammatory conditions associated with the musculoskeletal system in horses. In the treatment of inflammatory conditions associated with infections, specific anti-infective therapy should be used concurrently.

DOSAGE AND ADMINISTRATION: For Horses Only: Administer orally (using the 0.6 ounce (18 mL) scoop provided) on a small amount of palatable feed and mix well. Give 1 to 2 level scoops per 500 pounds of body weight, but do not exceed 4 scoops per animal daily. Use the high dose for the first 48 hours, then gradually reduce to a maintenance dose.

Each jar contains: 100 grams of phenylbutazone.

TAKE TIME OBSERVE LABEL DIRECTIONS

NDC 57699-001-22

EQUIZONE 100™

(phenylbutazone)

Powder
For Oral Use In Horses Only

NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extralabel use of this product in female dairy cattle 20 months of age or older.

Net Contents: 2.2 lb (1 kg)

Approved by FDA under ANADA # 200-334

Each 10 grams of powder contains:
Phenylbutazone ..... 1 gram
One level scoop delivers 10 grams of powder.

WARNING: Do not use in horses intended for human consumption.

HUMAN WARNINGS: Keep this and all medications out of the reach of children. Dispense in tight, child resistant containers.

PRECAUTION: Concomitant use with other anti-inflammatory drugs, such as NSAIDs or corticosteroids, should be avoided or closely monitored.

Store at room temperature, 15°-30°C (59°-86°F).

EQUIZONE 100™ is a trademark of A & G Pharmaceuticals, Inc.

Manufactured for
A & G Pharmaceuticals, Inc.
Jackson, NJ 08527

OPEN HERE

Lot No. Exp. Date

A&G Pharmaceuticals, Inc.

U.S. Patent #6,552,063 B2

Rev. 10-22

chronic equine arthritis of long duration, fair results in severely bruised mare and poor results in two cases where the condition was limited to the third phalanx.

HOW SUPPLIED: EQUIZONE 100 Powder is supplied in 2.2 lb (1 kg) jars each containing a dispensing scoop. One level scoop delivers 10 grams of powder containing 1 gram of phenylbutazone.

Store at room temperature, 15°-30°C (59°-86°F).

References:

1. Kuzell, WC, Schaffarzick, RW, Naughler, WE, Gandia, C, and Mankle, EA: A.M.A. Arch. Inst. Med., 92:646 (1953).
2. Kuzell, WC, Schaffarzick, RW, Brown, B, and Mankle, EA: J.A.M.A., 149:729 (1952).
3. Kuzell, WC, and Schaffazick, RW: Calif. Med., 77:319 (1952).
4. Payne, RW, Shelter, MR, Farr, CH, Hellbaum, AA, and Ishmall, WK: J. Lab. Clin. Med., 45:331 (1955).
5. Fleming, J, and Will, G: Ann. Rheumat., Dis., 12:95 (1953).

6. Denko, CW, and Rumi, D: American Pract., 6:1865 (1955).
7. Fabre, J, et al: Semain. Hop. (Paris), 31:87 (1955).
8. Domenjoz, R, et al: Arzneimittel-Forsch, 5:488 (1955).
9. Wilhelmi G, and Pulver, R: Arzneimittel-Forsch, 5:221 (1955).
10. Yourish, W, Paton, B, Brodie, B, and Burns, J: A.M.A. Arch. Ophth., 53:264 (1955).
11. Hazelton, LW, Tusing, TW, and Hollana, EG: J. Pharmacol. Exper. Ther., 109:387 (1953).
12. Ogilvie, FB, and Sutter, MD: Vet. Med. 52:492 (1957).
13. Camberos, HR: Rev. Med. Vet. (Buenos Aires), 38:9 (1956).
14. Sutter, MD: Vet. Med., 53:83 (1958).

Approved by FDA under ANADA # 200-334

Rev. 10-22

Each 10 grams of powder contains:
Phenylbutazone ..... 1 gram
One level scoop delivers 10 grams of powder.

WARNING: Do not use in horses intended for human consumption.

HUMAN WARNINGS: Keep this and all medications out of the reach of children. Dispense in tight, child resistant containers.

PRECAUTION: Concomitant use with other anti-inflammatory drugs, such as NSAIDs or corticosteroids, should be avoided or closely monitored.

Store at room temperature, 15°-30°C (59°-86°F).

EQUIZONE 100™ is a trademark of A & G Pharmaceuticals, Inc.

Manufactured for
A & G Pharmaceuticals, Inc.
Jackson, NJ 08527

EQUIZONE 100™

(phenylbutazone)

Powder
For Oral Use In Horses Only

NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extralabel use of this product in female dairy cattle 20 months of age or older.

DESCRIPTION: Phenylbutazone chemically is 4-butyl-1,2-diphenyl-3,5-pyrazolidinedione.

$C_{19}H_{20}N_2O_2$

Mol. Wt. 308.38

Each 10 grams of powder contains 1 gram phenylbutazone

INDICATIONS: Phenylbutazone is for the relief of inflammatory conditions associated with the musculoskeletal system in horses. In the treatment of inflammatory conditions associated with infections, specific anti-infective therapy should be used concurrently.

DOSAGE AND ADMINISTRATION: For Horses Only: Administer orally (using the 0.6 ounce (18 mL) scoop provided) on a small amount of palatable feed and mix well. Give 1 to 2 level scoops per 500 pounds of body weight, but do not exceed 4 scoops per animal daily. Use the high dose for the first 48 hours, then gradually reduce to a maintenance dose.

CONTRAINDICATIONS: Use with caution in patients who have history of drug allergy.

WARNING: Do not use in horses intended for human consumption.

HUMAN WARNINGS: Keep this and all medications out of the reach of children. Dispense in tight, child resistant containers.

PRECAUTION: Concomitant use with other anti-inflammatory drugs, such as NSAIDs or corticosteroids, should be avoided or closely monitored.

CLINICAL PHARMACOLOGY:
Phenylbutazone was first synthesized in 1948 and introduced into human medicine in 1949. Kuzell (1), (2), (3), Payne (4), Fleming (5) and Denko (6) demonstrated the clinical effectiveness of phenylbutazone in gout, gouty arthritis, acute arthritis, acute rheumatism and various other rheumatoid disorders in humans. Fabre (7), Domenjoz (8), Wilhelmi (9) and Yourish (10) have established the anti-rheumatic and anti-inflammatory activity of phenylbutazone. It is entirely unrelated to the steroid hormones.

Toxicity of phenylbutazone has been investigated in rats and mice (11) and dogs (12).

Phenylbutazone has been used by Camberos (13) in thoroughbred horses. Favorable results were reported in cases of traumatism, muscle rupture, strains and inflammations of the third phalanx. Results were not as favorable in the period treatment of osteoarthritis of the stifle and hip, arthrosis of the trapezious muscles and general arthritis. Sutter (14) reported a favorable response in

EQUIZONE 50/100

phenylbutazone powder

Product Information			
Product Type	PRESCRIPTION ANIMAL DRUG	**Item Code (Source)**	NDC:57699-001
Route of Administration	ORAL		

Active Ingredient/Active Moiety		
Ingredient Name	**Basis of Strength**	**Strength**
PHENYLBUTAZONE (UNII: GN5P7K3T8S) (PHENYLBUTAZONE - UNII:GN5P7K3T8S)	PHENYLBUTAZONE	1 g in 10 g

Product Characteristics			
Color	orange (Light orange powder)	**Score**	
Shape		**Size**	
Flavor	ORANGE (ORANGE FLAVOR)	**Imprint Code**	
Contains			

Packaging				
#	**Item Code**	**Package Description**	**Marketing Start Date**	**Marketing End Date**
1	NDC:57699-001-11	500 g in 1 JAR		
2	NDC:57699-001-22	1000 g in 1 JAR		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANADA	ANADA200334	02/18/2009	

Labeler - A&G Pharmaceuticals (182147033)

Revised: 10/2023 A&G Pharmaceuticals